HAVCR2 and diffuse large B-cell lymphoma: TIM-3+FOXP3+Treg cells could contribute to DLBCL development by secreting IL-10 in the TME, whereas antiTIM3 antibodies could be a potential future treatment regimen that blocks the secretion of IL-10 [35].